The start-up is preparing for a Phase III trial of its psoriasis product.
Meytag Technology Incubator portfolio company DermiPsor Ltd. is preparing for the Phase III clinical trial of its novel non-steroidal treatment for mild to moderate psoriasis, and is about to hold a financing round.
DermiPsor has also appointed Dr. Oren Becker as chairman. Becker was a founder of Predix, which merged to create Epix Pharmaceuticals Inc. (Nasdaq:EPIX) at a company value of $90 million.
DermiPsor did not disclose the size of the planned financing round, which is expected to fund the Phase III trial, which usually costs at least $5 million and can reach several times this amount. The treatment is based on Vitamins B and D.
Published by Globes [online], Israel business news - www.globes-online.com - on April 14, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008